魏辉，1973年生，籍贯辽宁，永利集团3044官网欢迎您血液病医院主任医师，博士生导师。1993年考入中国医科大学七年制专业，2000年获得硕士学位。2003年在中国协和医科大学内科学专业攻读博士学位，从事白血病的临床和基础研究。2010年进入美国国立卫生研究院做为访问学者从事白血病的耐药机制的研究工作。

从事白血病的临床和基础研究工作；对急性髓系白血病的发病及耐药机制进行研究，基于分子机制，开展靶向治疗策略研究；通过开展临床试验、建立临床队列完善优化急性白血病的诊疗体系。

1. Wei H#, Zhou C, Liu B, Lin D, Li Y, Wei S, Gong B, Zhang G, Liu K, Gong X, Fang Q, Liu Y, Qiu S, Gu R, Song Z, Chen J, Yang M, Zhang J, Jin J, Wang Y, Mi Y, Wang J*. The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm). Br J Haematol. 2022 May;197(4):442-451. (IF=5.908)

2. Wei H#, Wang Y#, Gale RP, Lin D, Zhou C, Liu B, Qiu S, Gu R, Li Y, Zhao X, Wei S, Gong B, Liu K, Gong X, Liu Y, Zhang G, Song Z, Wang Y, Li W, Mi Y*, Wang J*. Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia. Clin Cancer Res. 2020;26(13):3154-3161. (IF=9.937)

3. Wei H#, Zhou C, Lin D, Liu B, Li Y, Zhao X, Wei S, Gong B, Liu K, Gong X, Liu Y, Zhang G, Chen J, Zhang J, Jin J, Qiu S, Gu R, Wang Y, Mi Y, Wang J*. Benefit of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia. Haematologica. 2020; 106(5):1491-1495. (IF=7.116)

4. Yan D#, Wei H#, Lai X, Ge Y, Xu S, Meng J, Wen T, Liu J, Zhang W*, Wang J*, Xu H*. Co-delivery of homoharringtonine and doxorubicin boosts therapeutic efficacy of refractory acute myeloid leukemia. J Control Release. 2020; 327:766-778. (IF=7.835)

5. Wei H#, Wang Y, Zhou C, Lin D, Liu B, Liu K, Qiu S, Gong B, Li Y, Zhang G, Wei S, Gong X, Liu Y, Zhao X, Gu R, Mi Y, Wang J*. Distinct genetic alterationprofiles of acute myeloid leukemia between Caucasian and Eastern Asianpopulation. J Hematol Oncol. 2018; 11(1):18. (IF=6.649)

6. Wei H#, Xiang L, Wayne AS, Chertov O, FitzGerald DJ, Bera TK, Pastan I*. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proc Natl Acad Sci U S A. 2012; 109(18):6898-6903. (IF=9.628, F1000)

7. Wei H#,Bera TK, Wayne AS, Xiang L, Colantonio S, Chertov O, Pastan I*. A modified form ofdiphthamidecausesimmunotoxinresistance in a lymphomacelllinewith a deletionofthe WDR85 gene. J Biol Chem. 2013; 288(17): 12305-12312 (IF=4.971)